Compare Davita Inc (DVA) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Kroger Co — how do they compare? Davita Inc trades at $229.82 (market cap $14.92B), while Kroger Co trades at $58 (market cap $35.99B). The key difference: Kroger Co is far larger — about 2.4× Davita Inc's market cap, and Kroger Co pays a 2.45% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | KR | |
|---|---|---|
Market Cap | $14.92B | $35.99B |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $75.60 |
52-Week Low | $103.87 | $55.53 |
Enterprise Value | $27.47B | $56.08B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Kroger (KR) trades at $59.31, down 2.03% today, with technical indicators showing bearish momentum. The company maintains stable revenue around $147B with improving net margins (1.81% in 2025) and recently announced a $1.65B acquisition of Giant Eagle to expand Midwest presence. Strong cash flow generation ($2.08B net in 2025) supports dividend payments and strategic investments.
Kroger presents a mixed outlook with attractive valuation metrics (P/S 0.26) and analyst consensus target of $68.63 offering 16% upside potential. However, competitive pressures, recent earnings miss, and bearish technical signals warrant caution. The Giant Eagle acquisition provides growth opportunity but integration risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
